“Our strong first-quarter results reflect continued underlying operational sales and adjusted EPS growth. At the same time, we remain focused on investing in innovative technologies and platforms that will make a meaningful difference in the lives of patients around the world. I am proud of our global colleagues’ collective efforts to deliver on our long-term goals and our ability to create value for all of our stakeholders.”

**Worldwide Consumer Sales**

$3.3B
Consumer worldwide sales decreased: (2.4)%
Primary contributors to growth:

- Motrin
- TYLENOL
- Neutrogena

**Worldwide Pharmaceutical Sales**

$10.2B
Pharmaceutical worldwide sales increased: 4.1%
Primary contributors to growth:

- Stelara
- Imbruvica
- DARZALEX
- Symtuza

**Worldwide Medical Devices Sales**

$6.5B
Medical Devices worldwide sales decreased: (4.6)%
Primary contributors to growth:

- Electrophysiology
- Endovascular
- Accessory Contact Lenses